Current management of cutaneous melanomas of the head and neck

  • Samuel R. Fisher
  • Cameron A. Gillespie
  • Hilliard F. Seigler
  • Ian R. Crocker
Part of the Cancer Treatment and Research book series (CTAR, volume 32)


Cutaneous melanoma is a malignant neoplasm arising from melanocytes, which are the melanosome-containing cells that synthesize and transport melanin pigment. Whereas Carswell [1] is credited with the first modern clinical description of a malignant melanocyte neoplasm and suggested the term melanoma in 1834, Pemberton [2] in 1855 wrote one of the first reports of such a lesion originating in the head and neck region.


Neck Dissection Cutaneous Melanoma Primary Melanoma Advanced Malignant Melanoma Elective Neck Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Carswell, R., cited by Urega, O.B., Pack, E.T. 1966. On the antiquity of melanoma. Cancer 19: 607–610.Google Scholar
  2. 2.
    Pemberton, O. 1867. Clinical Illustrations of Various Forms of Cancer. Longmans, Green, Reader, and Dyer, London.Google Scholar
  3. 3.
    Elwood, J.M., Lee, J.A.H. 1975. Recent data on the epidemiology of malignant melanoma. Sem. Oncol. 2: 149–154.Google Scholar
  4. 4.
    Cosman, B., Heddle, S.B., Crikelair, G.F. 1976. The increasing incidence of melanoma. Plast. Recontr. Surg. 57: 50–56.Google Scholar
  5. 5.
    Schreiber, M.M., Bozzo, P.D., Moon, T.E. 1981. Malignant melanoma in Southern Arizona: Increasing incidence and sunlight as an etiologic factor. Arch. Dermatol. 117: 6–11.PubMedGoogle Scholar
  6. 6.
    Lee, J.A.H., Carter, A.P. 1970. Secular trends in mortality from malignant melanoma. J.N.C.I. 45: 91–97.Google Scholar
  7. 7.
    Luce, J.K., Mride, C.M., Frei, E., III. 1973. Melanoma. In Cancer Medicine. (J.F. Holland, E. Frei, III, eds.). Les & Frebiger, Philadelphia, pp. 1823–1844.Google Scholar
  8. 8.
    Gussack, G.S., Reintgen, D., Cox, E., Fusher, S.R., Cole, T.B., Seigler, H.F. 1983. Cutaneous melanoma of the head and neck: A review of 399 cases. Arch. Otolaryngol. 109: 803–808.PubMedGoogle Scholar
  9. 9.
    Hinds, M.W., Kolonel, L.N. 1980. Malignant melanoma of the skin in Hawaii, 1960–1977. Cancer 45: 811–817.PubMedGoogle Scholar
  10. 10.
    Krementz, E.T., Sutherland, C.M., Carter, R.D. et al. 1976. Malignant melanoma in the American Black. Ann. Surg. 183: 533–542.PubMedGoogle Scholar
  11. 11.
    Lancaster, H.O. 1956. Some geographical aspects on the mortality from melanoma. Med. J. Aust. 2: 1082–1087.Google Scholar
  12. 12.
    Anaise, D., Steinitz, R., Beur, N. 1978. Solar radiation: a possible etiologic factor in malignant melanoma in Israel. Cancer 42: 299–304.PubMedGoogle Scholar
  13. 13.
    Urbach, F. 1983. Sunlight and melanoma. J. Dermatol. Surg. Oncol. 9: 679–689.Google Scholar
  14. 14.
    Williams, R.R., Stegens, N.L., Goldsmith, J.R. 1977. Association of cancer site and type with occupation and industry from the Third National Cancer Survey Interview. J.N.C.I. 59: 1147–1185.Google Scholar
  15. 15.
    Lee J.A.H., Strickland, D. 1980. Malignant melanoma: Social status and outdoor work. Br. J. Cancer 42: 757–763.Google Scholar
  16. 16.
    Sober, A.J., Lew, R.A., Fitzpatrick, T.B. et al. 1979. Solar exposure patterns in patients with cutaneous melanoma. Clin, Res. 27: 573A.Google Scholar
  17. 17.
    Shaw, H.M., Milton, G.W., Farago, G. et al. 1978. Endocrine influences on survival from malignant melanoma. Cancer 42: 669–677.PubMedGoogle Scholar
  18. 18.
    Bhawan, J. 1979. Melanocytic nevi. A review. J. Cutan. Pathol. 6: 153–169.PubMedGoogle Scholar
  19. 19.
    Mihm, M.C., Jr., Clark, W.H., Jr. Reed, R.J. 1975. The clinical diagnosis of malignant melanoma. Sem. Oncol. 2: 105–118.Google Scholar
  20. 20.
    Fitzpatrick, T.B., Blichrest, B.A. 1977. Simple sign to differentiate benign from malignant pigmented cutaneous lesions. N. Engl. J. Med. 296: 1518.PubMedGoogle Scholar
  21. 21.
    Spitz S. 1948. Melanomas in childhood. Am. J. Pathol. 24: 591–609.PubMedGoogle Scholar
  22. 22.
    Paniago-Pereira, C., Maize, J.C., Ackerman, A.B. 1978. Nevus of large spindle cells and/or epitheloid cells (Spitz’s nevus). Arch. Dermatol. 114: 1811–1823.PubMedGoogle Scholar
  23. 23.
    Clark, W.H., Jr., Mihm, M.C. 1969. Lentigo maligna and lentigo maligna melanoma. Am. J. Pathol. 55: 39–67.PubMedGoogle Scholar
  24. 24.
    Bodenham, D.C. 1975. Malignant melanoma of the head and neck. In: Cancer of the Head and Neck (R.G. Chambers, ed.). Excerpta Medica, Amsterdam, pp. 85–91.Google Scholar
  25. 25.
    Conley, J., Hamaker, R.C. 1977. Melanoma of the head and neck. Laryngoscope 87: 760–764.Google Scholar
  26. 26.
    Byers, R.M., Smith, J.L., Russell, N., Rosenberg, V. 1980. Malignant melanoma of the external ear. Am. J. Surg. 140: 518–521.PubMedGoogle Scholar
  27. 27.
    Day, C.L., Sober, A.J., Kopf, A.W. et al. 1981. A prognostic model for clinical stage I melanoma of the upper extremitiy: The importance of anatomic subsites in predicting recurrent disease. Ann. Surg. 193: 436–440.PubMedGoogle Scholar
  28. 28.
    Brownstein, M.H., Helwig, E.B. 1972. Patterns of subcutaneous metastasis. Arch. Dermatrol. 105: 862–868.Google Scholar
  29. 29.
    Guiliana, A.E., Moseley, H.S., Morton, D.L. 1980. Clinical aspects of unknown primary melanoma. Ann. Surg. 191:98–104.Google Scholar
  30. 30.
    Garg, R., McPherson, T.A., Lentle, B. et al. 1979. Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma. Can. Med. Assoc. J. 120: 1114.PubMedGoogle Scholar
  31. 31.
    Murray, J.L., Lerner, M.P., Nordquist, R.E. 1982. Elevated gluatmyl transpeptidase levels in malignant melanoma. Cancer 49: 1439–1443.PubMedGoogle Scholar
  32. 32.
    Thomas, J.H., Panoussopoulous, D., Liesmann, G.E. et al. 1979. Scintiscans in the evaluation of patients with malignant melanoma. Surg. Gynecol. Obstet. 149: 574–576.PubMedGoogle Scholar
  33. 33.
    Evans, R.A., Bland, K.I., McMurtrey, M.J. et al. 1980. Radionuclide scans not indicated for clinical stage I melanoma. Surg. Gynecol. Obstet. 150: 532–534.PubMedGoogle Scholar
  34. 34.
    Kirkwood, J.M., Myers, J.E., Vlock, D.R. et al. 1982. Tomographic gallium-67 citrate scanning: Useful new surveillance for metastatic melanoma. Ann. Intern. Med. 97: 694–699.PubMedGoogle Scholar
  35. 35.
    Bydder, G.M., Kreel, L. 1981. Body computer tomography in the diagnosis of malignant melanoma metastases. C.T. 5: 21–24.Google Scholar
  36. 36.
    Musumeci, R., Acerbil, L., Balzarina, G.P. et al. 1972. Lymphographic evaluation of 116 cases of malignant melanoma. Tumor 58: 1–12.Google Scholar
  37. 37.
    Cox, K., Hare, W.S.C., Bruce, P.T. 1966. Lymphography in melanoma. Cancer 19: 637–647.PubMedGoogle Scholar
  38. 38.
    Reintgen, D.S., Sullivan, D., Coleman, E., Briner, W., Croker, B.P., Seigler, H.F. 1983. Lymphoscintography for malignant melanoma: surgical considerations. Am. Surg. 49, 12: 672–678.PubMedGoogle Scholar
  39. 39.
    Roses, D.F., Ackerman, A.B., Harris, M.N. et al. 1979. Assessment of biopsy techniques and histopathologic interpretations of primary cutaneous malignant melanoma. Ann. Surg. 189: 294—297.PubMedGoogle Scholar
  40. 40.
    Little, J.H., Davis, N.C. 1974. Frozen section diagnosis of suspected malignant melanoma of the skin. Cancer 34: 1163–1172.PubMedGoogle Scholar
  41. 41.
    Epstein, E., Bragg, K., Linden, G. 1969. Biopsy and prognosis of malignant melanoma. J.A.M.A. 208: 1369–1371.PubMedGoogle Scholar
  42. 42.
    Clark, Jr., W.H., From, L., Bernadina, E.A., Mihm, Jr., M.C. 1969. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29: 705–726.PubMedGoogle Scholar
  43. 43.
    Balch, C.M., Murad, T.M., Soong, S.J. et al. 1978. A multifactorial analysis of melanoma: Prognostic histopathologic features comparing Clark’s and Breslow’s staging methods. Ann. Surg. 118: 732–742.Google Scholar
  44. 44.
    Breslow, A. 1975. Tumor thickness, level of invasion, and node dissection in stage I cutaneous melanoma. Ann. Surg. 182: 572–575.PubMedGoogle Scholar
  45. 45.
    Breslow, A. 1979. Prognostic factors in the treatment of cutaneous melanoma. J. Cutan. Pathol. 6: 208–212.PubMedGoogle Scholar
  46. 46.
    Wanebo, H.J., Fortner, J.G., Woodruff, J. et al. 1975. Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: Use of the combined microstage technique (Clark-Breslow). Ann. Surg. 188: 302–315.Google Scholar
  47. 47.
    Day, Jr., C.L., Lew, R.A., Mihm, Jr., M. c. et al. 1981. A multivariate analysis of prognostic factors for melanoma patients with lesions 3.65 mm in thickness. The importance of revealing alternate Cox models. Ann. Surg. 195: 44–49.Google Scholar
  48. 48.
    Day, Jr., C.L., Mihm, Jr., M.C., Lew, R.A. et al. 1982. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51–3.99mm). A conceptual model for tumor growth and metastasis. Ann. Surg. 195: 35–43.PubMedGoogle Scholar
  49. 49.
    Van der Esch, E.P., Cascinelli, N., Preda, F. et al. 1981. Stage I melanoma of the skin: Evaluation of prognosis according to histologic characteristics. Cancer 48: 1668–1673.Google Scholar
  50. 50.
    Beahrs, O.H., Myers, M.H. 1983. Manual for staging of cancer, American Joint Committee on Cancer. J.B. Lippincott, Philadelphia, pp. 117–123.Google Scholar
  51. 51.
    Ames, F.C., Sugarbaker, E.V., Ballantyne, A.S. 1976. Analysis of survival and disease control in stage I melanoma of the head and neck. Am. J. Surg. 132: 484–491.PubMedGoogle Scholar
  52. 52.
    Das Gupta, T.K. 1977. Results of treatment of 269 patients with primary cutaneous melanoma: A five-year prospective study. Ann. Surg. 186: 201–209.Google Scholar
  53. 53.
    Knutson, C.D., Hori, J.M., Watson, F.R. 1981. Melanoma of the head and neck. Am. J. Surg. 124: 470–473.Google Scholar
  54. 54.
    Handley, W.S. 1907. The pathology of melanotic growths in relation to their operative treatment. Lancet 1: 927–10003.Google Scholar
  55. 55.
    Wilson, R. 1958. Malignant melanoma – a follow-up study. West. J. Surg. Obstet. Gynecol. 66: 19–31.Google Scholar
  56. 56.
    Meer, G., Cantin, J. 1967. Local failure in the treatment of melanoma. Am. J. Roentgen, Rad. Ther. Nucl. Med. 99: 790–808.Google Scholar
  57. 57.
    Jones, W.M., Williams, W.J., Roberts, M.M. et al. 1968. Malignant melanoma of the skin: Prognostic value of clinical features and the role of treatment in 111 cases. Br. J. Cancer 22: 437–451.PubMedGoogle Scholar
  58. 58.
    Shingleton, W.W., Seigler, H.F., Stocks, L.H. et al. 1975. Management of recurrent melanoma of the extremity. Cancer 35: 574–579.PubMedGoogle Scholar
  59. 59.
    Elias, E.G., Didolkar, M.S., Goel, T.P. et al. 1977. A clinicopathologic study of prognostic factors in cutaneous malignant melanoma. Surg. Gynecol. Obstet. 144: 327–334.PubMedGoogle Scholar
  60. 60.
    Karakousis, C.P., Holyoke, E.D. 1980. Biologic behavior and treatment of intransit metastasis of melanoma. Surg. Gynecol. Obstet. 150: 29–32.PubMedGoogle Scholar
  61. 61.
    Milton, G.W., Shaw, H.N., Farago, G.A. et al. 1980. Tumor thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I). Br. J. Surg. 67: 543–546.PubMedGoogle Scholar
  62. 62.
    Cascinelli, N., Van der Essche, E.P., Breslow, A. et al. 1980. Stage I melanoma of the skin: the problem of resection margins. Eur. J. Cancer 16: 1079–1085.Google Scholar
  63. 63.
    Golomb, F.M. 1983. Discussion of two papers entitled ‘Optimal resection margin for cutaneous melanoma’ and ‘Patients perception of the cosmetic impact of melanoma resection’. Plast. Reconstr. Surg. 71: 76–78.Google Scholar
  64. 64.
    Cosimi, A.B., Sober, A.J., Mihm, M.C., Fitzpatrick, T.B. 1984. Conservative surgical management of superficially invasive cutaneous melanoma. Cancer 56: 1256–9.Google Scholar
  65. 65.
    Bagley, F.H., Cady, B., Lee, A., Legg, MA. 1981. Changes in clinical presentation and management of malignant melanoma. Cancer 47: 2126–34.PubMedGoogle Scholar
  66. 66.
    Patel, J.K., Didolkan, M.S., Pickren, J.W., Moore, R.H. 1978. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135: 807–10.PubMedGoogle Scholar
  67. 67.
    Olson, R.M., Woods, J.E., Soule, E.H. 1981. Regional lymph node management and outcome in 100 patients with head and neck melanoma. Am. J. Surg. 142: 470.PubMedGoogle Scholar
  68. 68.
    Day, C.L., Mihm, M.C., Lew, R.A., Kopf, A.W., Sober, A.J., Fritzpatrick, T.B. 1982. Cutaneous malignant melanoma: Prognostic guidelines for physicians and patients. C.A. 32(2): 113–122.Google Scholar
  69. 69.
    Balch, C.M. 1980. Surgical management of regional lymph nodes in cutaneous melanoma. J. Am. Acad. Dermatol. 3(5): 511–24.PubMedGoogle Scholar
  70. 70.
    Simons, J.N. 1972. Malignant melanoma of the head and neck. Am. J. Surg. 125: 485–488.Google Scholar
  71. 71.
    Harris, T.J., Hinckley, D.M. 1983. Melanoma of the head and neck in Queensland. Head Neck Surg. 5(3): 197–203.PubMedGoogle Scholar
  72. 72.
    Storm, F.K., Eilber, F.R. 1981. The value of lymphadenectomy in melanoma of the head and neck. In: Head and Neck Oncology: Controversies in Cancer Treatment (A.R. Kagan, J.W. Miles, zds.). G.K. Hall, Boston, pp. 127–138.Google Scholar
  73. 73.
    Balch, C.M., Milton, G.W., Shaw, H.M., Soong, S.J. 1985. Elective lymph node dissection: Pros and cons. In: Cutaneous Melanoma (C.M. Balch, G.W. Milton, H.M. Shaw, S.J. Soong, eds.). Lippincott, Philadelphia, pp. 131–157.Google Scholar
  74. 74.
    Kapelanski, D.P., Block, G.E., Kaufman, M. 1979. Characteristics of the primary lesion of malignant melanoma as a guide to prognosis and therapy. Ann. Surg. 189: 225–235.PubMedGoogle Scholar
  75. 75.
    Balch, C.M. 1982. Pathology, prognostic factors and surgical treatments of cutaneous melanoma. Curr. Concepts Oncol. 4: 8.Google Scholar
  76. 76.
    Sim, F.H., Taylor, W.F., Ivins, J.C. et al. 1978. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 41: 948–956.PubMedGoogle Scholar
  77. 77.
    Day, C.L., Sober, A.J., Lew, R.A. etal. 1981. Malignant melanoma patients with positive nodes and relatively good prognosis: Microstaging retains prognostic-significance in clinical stage I melanoma patients with metastasis to regional nodes. Cancer 47: 955–962.PubMedGoogle Scholar
  78. 78.
    Fortner, J.G., Woodruff, J., Schottenfeld, D. 1977. Biostatistical basis of elective node dissection for malignant melanoma. Ann. Surg. 186: 101–103.PubMedGoogle Scholar
  79. 79.
    Conley, J.J., Pack, G.T. 1963. Melanoma of the head and neck. Surg. Gynecol. Obstet. 116: 15–28.PubMedGoogle Scholar
  80. 80.
    Lingemen, R.E. et al. 1977. Neck dissection: Radical or conservative, Ann. Otol. 86: 737.Google Scholar
  81. 81.
    Bocca, E., Pignataro, O., Oldini, C., Cappa, C. 1984. Functional neck dissection: An evaluation and review of 843 cases, Laryngoscope 94: 942.PubMedGoogle Scholar
  82. 82.
    Molinari, R., Cantu, E., Chicsa, F., Grandi, C. 1980. Restrospective comparison of conservative and radical neck dissection in laryngeal cancer. Ann. Otol. 89: 578–581.Google Scholar
  83. 83.
    Seigier, H.F., Cox, E., Mutzner, F. et al. 1979. Specific active immunotherapy for melanoma. Ann. Surg. 190: 366–372.Google Scholar
  84. 84.
    Everall, J.D., O’Doherty, C.J., Ward, J. et al. 1975. Treatment of primary melanoma with intralesional vaccinia before excision. Lancet 2: 583–586.PubMedGoogle Scholar
  85. 85.
    Casterman-Elias, S., Simar, L., Vanijck, R. et al. 1977. Immunosurgical treatment of stage I malignant melanoma. Cancer Immunol. Immunother. 2: 179–187.Google Scholar
  86. 86.
    Rosenberg, S.A., Rapp, H., Terry, W. et al. 1982. Intralesional BCG therapy of patients with primary stage I melanoma. In: Immunotherapy of Human Cancer (W.D. Terry, S.A. Rosenberg, eds.). Elsevier North Holland, New York, pp. 289–291.Google Scholar
  87. 87.
    Comis, R.I. 1976. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat. Rep. 60: 165–176.PubMedGoogle Scholar
  88. 88.
    Luce, J.K. 1972. Chemotherapy of malignant melanoma. Cancer 30: 1604–1616.PubMedGoogle Scholar
  89. 89.
    Bellet, R.E., Mastrangelo, M.J., Laucius, J.F. et al. 1976. Randomized perspective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat. Rep. 60: 595–600.Google Scholar
  90. 90.
    Luce, J.K., Thurman, W.G., Isaacs, B.L. et al. 1970. Clinical trials with the antitumor agent 5-(3,3,-dimethy-l-triazeno) imidazole-4-carboxamide (NSC 45388). Cancer Chemother. Rep. 54: 119–124.PubMedGoogle Scholar
  91. 91.
    Rochlin, D.B., Wagner, D.E., Wilson, W.L., Weber, A.P. 1970. Results of phase I and II studies with imidazole-carboxamide-dimethyl-triazene (Abstr. 768). Tenth Int. Cancer Congress, Houston.Google Scholar
  92. 92.
    Burke, P.J., McCarthy, W.H., Milton, G.W. 1971. Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 27: 744–750.PubMedGoogle Scholar
  93. 93.
    Wagner, D.E., Ramirez, G., Weiss, A.J., Hill, G.J. 1972. Combination phase I-II study of imidazole carboxamide. Oncology 26: 310–316.PubMedGoogle Scholar
  94. 94.
    Czarnetzki, B.M., Macher, E. 1981. DTIC (dacarbazine)-induced hepatic damage. Arch. Dermatol. Res. 270: 375–376.PubMedGoogle Scholar
  95. 95.
    Frosch, P.J., Czarnetzki, B.M., Macher, E. et al. 1979. Hepatic failure in a patient treated with DTIC for malignant melanoma. J. Cancer Res. Clin. Oncol. 95: 281–286.PubMedGoogle Scholar
  96. 96.
    Greenstone, M.A., Dowd, Pm., Mikhailidis, D. p., et al. 1981. Hepatic vascular lesions associated with dacarbazine treatment. Br. Med. J. 182: 1744–1745.Google Scholar
  97. 97.
    Feaux de Lacroix, W., Runne, U., Hauk, H. et al. 1983. Acute liver dystrophy with thrombosis of hepatic veins: A fatal complication of Dacarbazine treatment, Cancer Treat, Rep. 67: 779–784.Google Scholar
  98. 98.
    Rzmirez, G., Wilson, W., Grage, T. et al. 1972. Phase II evaluation of l,3-bis(2-chloroethyl-nitrosourea) (BCNU; NSC-409962) in patients with solid tumors. Cancer Chemother. Rep. 56: 787–790.Google Scholar
  99. 99.
    Ahmann, D.L., Hahn, R.G., Bisel, H.F. 1972. A comparative study of l-(2-chloroethyl)-3-cyclo-hexyl-1-nitrosourea (NSC-79037) and imidazole carboxamide (NSC-45388) with vincristine (NSC-67574) in the palliation of disseminated malignant melanoma. Cancer Res. 32: 2432–2434.PubMedGoogle Scholar
  100. 100.
    Ahmann, D.L., Hahn, R.G., Bisel, H.F. 1974. Evaluation of 1-(2-chloroethyl-3-4-methyl-cyclo-hexyl)-1-nitrosourea (methyl-CCNU, NSC-95441) versus combined imidazole carboxamide (NSC-45388) and vincristine (NSC-67574) in palliation of disseminated melanoma. Cancer 33: 615–618.PubMedGoogle Scholar
  101. 101.
    Van Amburg, A.L., Presant, C.A., Burns, D. 1982. Phase II study of chlorozotocin in malignant melanoma: A Southeastern Cancer Study Group report. Cancer Treat. Rep. 66: 1431–1433.PubMedGoogle Scholar
  102. 102.
    Ahmann, D.L., Hahn, R.G., Bisel, H.F. et al. 1975. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-l-triazeno) imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated melanoma. Cancer Chemother. Rep. 59: 451–453.PubMedGoogle Scholar
  103. 103.
    Cauverqne, J., Clavel, B., Klein, T. et al. 1978. Chemotherapy of malignant melanoma. Bull. Cancer 65: 107–109.Google Scholar
  104. 104.
    Wittes, R.E., Wittes, J.T., Golbey, R.B. 1978. Combination chemotherapy in metastatic melanoma. Cancer 41: 415–421.PubMedGoogle Scholar
  105. 105.
    Rersas, S., Athanasiou, A., Flynn, M.D. et al. 1982. Combined chemotherapy with vindesine and DTIC in advanced malignant melanoma. Proc. Am. Soc. Clin. Oncol. 1: 169.Google Scholar
  106. 106.
    Gerner, R.E., Moore, G.E., Dickey, C. 1975. Combination chemotherapy in disseminated melanoma and other solid tumors in adults. Oncology 31: 22–30.PubMedGoogle Scholar
  107. 107.
    Goodnight, J.E., Jr., Moseley, H.S., Eilber, F.R. et al. 1979. Cis-dichloro-diammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat. Rep. 63: 2005–2007.PubMedGoogle Scholar
  108. 108.
    Friedman, M. a., Kaufman, D.A., William, J.E. et al. 1979. Combined DTIC and cis-dichloro-diammineplatinum (II) therapy for patients with disseminated melantfma: A Northern California Oncology Group study. Cancer Treat. Rep. 63: 493–495.PubMedGoogle Scholar
  109. 109.
    Byrne, J.M., Reynolds, P.M. 1982. Phase II study of cyclophosphamide, vincristine and DTIC + BCG in the treatment of malignant melanoma. Aust. N.Z. J. Med. 12: 263–266.PubMedGoogle Scholar
  110. 110.
    Samson, M.K., Baker, L.H., Cummings, G. et al. 1982. Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma. Cancer Treat. Rep. 663: 371–373.Google Scholar
  111. 111.
    Carey, R.W., Green, M.R., Anderson, J. 1983. Vinblastine-dimethyltriazenoimidazole carboxamide (DTIC)-cis-platinum (VDP): Active regimen in metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 2: 237.Google Scholar
  112. 112.
    Ahn, S.S., Giuliano, A., Kaiser, L. et al. 1983. The limited role of BOLD chemotherapy for disseminated malignant melanoma. Proc. Am. Soc. Clin. Oncol. 2: 228.Google Scholar
  113. 113.
    Cohen, S.M., Ohnuma, T., Cheung, T. et al. 1983. Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastastic melanoma. Clin Treat. Rep. 67: 947–948.Google Scholar
  114. 114.
    York, R.M., Lawson, D.H., May, J. 1983. Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer 52: 2220–2222.PubMedGoogle Scholar
  115. 115.
    Mechl, Z., Nekulova, M., Sopkova, B. et al. 1983. The VBD regimen (vinblastine-bleomycin-cis-platinum) with high doses of cisplatinum in the therapy of advanced malignant melanoma. Proc. 13th Int. Cong. Chemother., part 246, pp. 22–25.Google Scholar
  116. 116.
    Pugh, R., Jacobs, E., Bateman, L. et al. 1974. In: Proceedings of the 11th International Cancer Congress, Florence.Google Scholar
  117. 117.
    Cruz, A.B., Jr., Armstong, D.M., Aust, J.B. 1974. Treatment of advanced malignancy with CCNU (l-(2-chlomethyl)-3-cyclohexyl-l-nitrosourea (NSC 74037). A phase II cooperative study. Proc. Am. Assoc. Cancer Res. and Am. Soc. Cun. Oncol. 15: 184.Google Scholar
  118. 118.
    Dasch, G., Bernheim, J., Michel, J. et al. 1976. Combination chemotherapy with three marginally effective agents, CCNU, vincristine and bleomycin in the treatment of Stage III melanoma. Cancer Treat. Rep. 60: 1273–1276.Google Scholar
  119. 119.
    Seigler, H.F., Lucas, S., Pickett, N.J., Huang, A.T. 1980. DTIC, CCNU, Bleomycin, and Vincristine (BOLD) in Metastatic Melanoma. Cancer 46(1): 2346–2348.PubMedGoogle Scholar
  120. 120.
    Wick, M.M., Byers, L., Frei, E., I.I.I. 1977. L-Dopa: Selective toxicity for melanoma cells in vitro. Science 197: 468–469.PubMedGoogle Scholar
  121. 121.
    Nathason, L., Hall, F.C., Fiarber, S. 1967. Biological aspects of human malignant melanoma. Cancer 20: 650–655.Google Scholar
  122. 122.
    Myhre, E. 1963. Malignant melanoma in children, Acta Pathol. Microbiol. Scand, 59: 184–188.Google Scholar
  123. 123.
    Sadoff, L., Winkley, J., Tyson, S. 1973. Is malignant melanoma an endocrine dependent tumor? Oncology 27: 244–257.PubMedGoogle Scholar
  124. 124.
    Shiu, M.H., Schottenfield, D., Maclean, B., Fortner, J.G. 1976. Adverse effect of pregnancy on melanoma. Cancer 37: 181–187.PubMedGoogle Scholar
  125. 125.
    George, P.A., Fortner, J.G., Pack, G.T. 1960. Melanoma with pregnancy. Cancer 13(4): 854–859.PubMedGoogle Scholar
  126. 126.
    McCarty, K.S., Jr., Wortman, J., Stowers, S. et al. 1980. Sex steroid receptor analysis in melanoma. Cancer 46: 157–164.Google Scholar
  127. 127.
    Zava, D.T., Goldhirsch, A. 1983. Estrogen receptor in malignant melanoma: fact or artefact? Eur. J. Cancer Clin. Onol. 19(8): 1151–9.Google Scholar
  128. 128.
    Johnson, R.O., Bisel, H.F., Andrews, N. et al. 1966. Phase I clinical study of 6-methylpregn-4- ene-e, 11, 20-trione (NSC-17256). Cancer Chemother. Rep. 50: 671–673.Google Scholar
  129. 129.
    Lopex, R., Karakousis, C.P., Didolkar, M. s. et al. 1978. Estramustine phosphate (estracyt) in advanced malignant melanoma. Cancer Treat. Rep. 62: 1329–1332.Google Scholar
  130. 130.
    Didolkar, M.S., Catane, R., Lopez, R., Holyoke, E.D. 1978. Estramustine phosphate (estracyt) in advanced malignant melanoma resistant to DTIC treatment, Proc. Am. Assoc. Cancer Res. 19: 381.Google Scholar
  131. 131.
    Fisher, R.I., Young, R.C., Lippman, M.C. 1978. Diethylstilbestrol therapy of surgically non-resectable malignant melanoma. Proc. Am. Assoc. Cancer Res. 19: 339.Google Scholar
  132. 132.
    Beretta, G., Tabiadon, D., Fossati, P. 1979. Clinical evaluation of medroxiprogesterone acetate (MAP) in malignant melanoma. Cancer Treat. Rep. 63: 1200.Google Scholar
  133. 133.
    Creagan, E.T., Schutt, A.J., Ahmann, D.L. et al. 1982. Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat. Rep. 66: 1239–1240.PubMedGoogle Scholar
  134. 134.
    Meyskens, F.L., Jr., Yoakes, J.B. 1980. Tamoxifen in metastatic malignant melanoma. Cancer Treat. Rep. 64: 171–173.PubMedGoogle Scholar
  135. 135.
    Harwood, A.R., Cummings, B.J. 1981. Radiotherapy for malignant melanoma: a reappraisal. Cancer Treat. Rev. 8: 271–282.Google Scholar
  136. 136.
    Dewey, D.L. 1971. The radiosensitivity of melanoma cells in culture. Br. J. Radiol. 44: 816–816.PubMedGoogle Scholar
  137. 137.
    Hornsey, S. 1972. The radiation response of human malignant melanoma cells in vitro and in vivo. Cancer Res. 32: 650–651.PubMedGoogle Scholar
  138. 138.
    Habermalz, H.J., Fisher, J.J. 1976. Radiation therapy of malignant melanoma. Experience with high individual treatment doses. Cancer 38: 2258–2262.PubMedGoogle Scholar
  139. 139.
    Overgaard, J. 1980. Radiation treatment of malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 6: 41–44.PubMedGoogle Scholar
  140. 140.
    Hornsey, S. 1970. The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients. Br. Radiol. 51: 905–909.Google Scholar
  141. 141.
    Lobo, P.A., Liebner, E.J., Chao, J.J.-H., Kanji, A.M. 1981. Radiotherapy in the management of malignant melanoma. Int, J. Radiat. Oncol. Biol. Phys. 7: 21–16.Google Scholar
  142. 142.
    Trott, K.R., von Lieven, H., Kummermehr, J., Skopal, D., Lukacs, S., Braun-Falco, O., Kellerer, A.M. 1981. The radiosensitivity of malignant melanomas. Part II: Clinical studies. Int. J. Radiat. Oncol. Biol. Phys. 7: 15–20.PubMedGoogle Scholar
  143. 143.
    Harwood, A.R. 1982. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol. 6(3): 310–316.PubMedGoogle Scholar
  144. 144.
    Harwood, A.R. 1983. Lentigo maligna melanoma yields to radiotherapy. Report of the American Society of Therapeutic Radiologists. J.A.M.A. 249(3): 323–327.Google Scholar
  145. 145.
    Braun-Falco, O., Lucas, S., Schoefinius, H. 1975. Zurbehandlung der melanosis cercusmscripta praecancerosa. Dubreuilh. Hantartz 26: 207–210.Google Scholar
  146. 146.
    Hellriegel, W. 1963. Radiation therapy of primary and metastatic melanoma. Ann. N.Y. Acad. Sci. 100: 131–141.PubMedGoogle Scholar
  147. 147.
    Jorgsholm, B., Engdahl, I. 1955. Malignant melanoma. Acta Radiol. 44: 417–433.PubMedGoogle Scholar
  148. 148.
    Dickson, R.J. 1958. Malignant melanoma: a combined surgical and radiotherapeutic approach. 79: 1063–1070.Google Scholar
  149. 149.
    Nitter, L. 1962. The treatment of malignant melanonce with special reference to the possible effect of radiotherapy. Acta Radiol. 46: 547–562.Google Scholar
  150. 150.
    Creagan, E.T., Cupps, R.E., Ivins, I.C. et al. 1978. Adjuvant radiation therapy for regional nodal metastasis from malignant melanoma. A randomized study. Cancer 42: 2206–2210.PubMedGoogle Scholar
  151. 151.
    Hilaris, B.S., Raben, M., Calabrese, A.S. et al. 1963. Value of radiation therapy for distant metastases from malignant melanoma. Cancer 16: 765–773.PubMedGoogle Scholar
  152. 152.
    Katz, H.R. 1981. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. Int. J. Radiat. Oncol. Biol. Phys. 7: 907–911.PubMedGoogle Scholar
  153. 153.
    McNeer, G., Das Gupta, T. 1964. Prognosis in malignant melanoma. Surgery 56: 512–518.Google Scholar
  154. 154.
    Guichard, M., Tenforde, T., Curtis, S., Malaise, E.P. 1982. Effect of combined misonidazole and accelerated neon ions on a human melanoma transplanted into nude mice. Radiology 142: 219–23.PubMedGoogle Scholar
  155. 155.
    Perez, C.A., Kopeckey, W., Rao, D.V., Baglan, R., Mann, J. 1981. Local microwave hyperthermia and irradiation in cancer therapy: preliminary observations and directions for future clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 7: 765–72.PubMedGoogle Scholar
  156. 156.
    Kim, J.H., Hahn, E.W., Ahmed, S.A. 1982. Combination hyperthermia and radiation therapy for malignant melanoma. Cancer 50: 478–482.PubMedGoogle Scholar
  157. 157.
    Corry, P.M., Spanos, W.J., Tilchen, E.J. et al. 1982. Combined ultrasound and radiation therapy treatment of human superficial tumors. Radiology 145: 165–169.PubMedGoogle Scholar
  158. 158.
    Noell, U.R.T., Woodward, K.T., et al. 1980. Microwave-induced local hyperthermia in combination with radiotherapy of human malignant tumors. Cancer 45: 638–646.PubMedGoogle Scholar
  159. 159.
    Verhey, L.J., Munzenrider, J.E. 1982. Proton beam therapy. Ann. Rev. Biophys. Bioeng. 2: 331–57.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Samuel R. Fisher
  • Cameron A. Gillespie
  • Hilliard F. Seigler
  • Ian R. Crocker

There are no affiliations available

Personalised recommendations